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he low density lipoprotein receptor–related protein
(LRP-1) binds and mediates the endocytosis of multiple
ligands, transports the urokinase-type plasminogen
activator receptor (uPAR) and other membrane proteins
into endosomes, and binds intracellular adaptor proteins
involved in cell signaling. In this paper, we show that in
murine embryonic ﬁbroblasts (MEFs) and L929 cells, LRP-1
functions as a major regulator of Rac1 activation, and that
this activity depends on uPAR. LRP-1–deﬁcient MEFs demon-
strated increased Rac1 activation compared with LRP-1–
expressing MEFs, and this property was reversed by express-
ing the VLDL receptor, a member of the same gene family
as LRP-1, with overlapping ligand-binding speciﬁcity.
Neutralizing the activity of LRP-1 with receptor-associated
T
 
protein (RAP) increased Rac1 activation and cell migration
in MEFs and L929 cells. The same parameters were unaffected
by RAP in uPAR
 
 
 
/
 
 
 
 MEFs, prepared from uPAR gene knock-
 
out embryos, and in uPAR-deﬁcient LM-TK
 
 
 
 cells. Untreated
uPAR
 
 
 
/
 
 
 
 MEFs demonstrated substantially increased Rac1
activation compared with uPAR
 
 
 
/
 
 
 
 MEFs. In addition to
Rac1, LRP-1 suppressed activation of extracellular signal–
regulated kinase (ERK) in MEFs; however, it was Rac1 (and
not ERK) that was responsible for the effects of LRP-1 on MEF
migration. Thus, LRP-1 regulates two signaling proteins in the
same cell (Rac1 and ERK), both of which may impact on cell
migration. In uPAR-negative cells, LRP-1 neutralization does
not affect Rac1 activation, and other mechanisms by which
LRP-1 may regulate cell migration are not unmasked.
 
Introduction
 
Receptors in the low density lipoprotein receptor gene
family (LRFs)* are type I transmembrane proteins with
common structural modules, including EGF-like repeats,
complement-like repeats, and YWTD-containing repeats
(Strickland et al., 2002). LRFs may localize to clathrin-
coated pits and/or caveolae and typically undergo constitutive
endocytosis and recycling (Goldstein et al., 1979; Weaver
et al., 1996; Li et al., 2001; Boucher et al., 2002). Some of
the better-characterized LRFs, including the low density lipo-
protein receptor–related protein (LRP-1), gp330/megalin
(LRP-2), and the VLDL receptor (VLDLr) bind multiple
ligands with partially overlapping specificity, including
proteinases, proteinase–inhibitor complexes, ECM proteins,
hormones, growth factors, and foreign proteins (Strickland
et al., 2002). Bound ligands are internalized and then usually
transported to lysosomes for degradation.
LRFs frequently bind proteins that are already associated
with other cell-surface receptors or binding sites in the same
cell. For example, protease nexin 1–proteinase complexes
bind first to heparan sulfate proteoglycans and then to LRP-1
(Knauer et al., 1997). Urokinase-type plasminogen activator
(uPA)–plasminogen activator inhibitor-1 (PAI-1) complex,
which forms in association with the uPA receptor (uPAR),
rapidly binds to LRP-1 or the VLDLr (Conese et al., 1995;
Webb et al., 1999). Similarly, factor VIIa–tissue factor pathway
inhibitor complex, which forms in association with tissue
factor, binds to LRP-1 (Hamik et al., 1999). In these examples,
LRP-1 internalizes not only the ligand, but may also internalize
the bridged receptor and thereby decrease the level of the
second receptor in the plasma membrane. The plasma
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membrane–associated proteinase inhibitor, amyloid precur-
sor protein (APP), undergoes LRP-1–facilitated endocytosis
due to two distinct interactions, the first involving the extra-
cellular domains of APP and LRP-1, which associate after
APP binds proteinase; and the second involving intracyto-
plasmic domains of APP and LRP-1, which are bridged by
the bifunctional adaptor protein, Fe65 (Ulery et al., 2000;
Kinoshita et al., 2001). By these mechanisms, LRP-1 re-
models the plasma membrane and may indirectly regulate
the ability of the cell to respond to growth factors and other
regulatory molecules.
LRFs also function as signaling coreceptors for diverse
ligands. The VLDLr and apoER2 are essential components
of the reelin-initiated cell signaling pathway that controls
development of the central nervous system (D’Arcangelo et
al., 1999; Trommsdorff et al., 1999). Similarly, LRP-6 func-
tions as a coreceptor in Wnt signaling (Tamai et al., 2000).
NPxY motifs, which are found in the intracytoplasmic do-
mains of many LRFs, bind proteins involved in cell signal-
ing, including Dab-1, Fe65, Shc, Jun kinase–interacting
protein, and ced-6/GULP (Gotthardt et al., 2000; Barnes et
al., 2001; Su et al., 2002). These interactions, which are reg-
ulated by NPxY tyrosine phosphorylation, may promote ac-
tivation of signaling proteins or sequester signaling proteins,
preventing their transfer to effector sites such as the nucleus.
In murine embryonic fibroblasts (MEFs) and HT 1080 fi-
brosarcoma cells, loss of LRP-1 expression is associated with
increased uPA accumulation in the medium, increased cell
surface uPAR, and increased cell migration on vitronectin-
coated surfaces (Weaver et al., 1997; Webb et al., 2000).
Similar changes are observed when the activity of the
VLDLr is neutralized in MCF-7 breast cancer cells (Webb et
al., 1999). In the HT 1080 and MCF-7 cells, uPA and
uPAR establish an autocrine signaling pathway in which Ras
and extracellular signal–regulated kinase (ERK) are activated
(Ossowski and Aguirre-Ghiso, 2000; Webb et al., 2000).
ERK and its downstream effector, myosin light chain kinase
(MLCK), are responsible for the increase in cell migration
(Nguyen et al., 1999; Webb et al., 2000); however, ERK
does not control cell migration in all cell types. Factors that
may influence whether cell migration is regulated by ERK
include integrin expression and the biochemical composi-
tion of the migration substratum (Yebra et al., 1996;
Klemke et al., 1997; Nguyen et al., 1999).
The function of LRP-1 as a regulator of cell-surface uPAR
suggests mechanisms other than activation of the Ras–ERK
pathway whereby LRP-1 may affect cell migration. Kjoller
and Hall (2001) demonstrated that uPAR overexpression
promotes cell migration by activating the small GTPase,
Rac1. This effect did not require uPA, but instead involved
direct binding of uPAR to vitronectin, a previously docu-
mented uPAR ligand (Wei et al., 1994). Activated Rac1 reg-
ulates the activity of terminal effector proteins such as Arp2/3
complex, cofilin, and actin capping protein to initiate and
stabilize new actin polymerization in advancing lamellipodia
of the migrating cell (Kraynov et al., 2000; Ridley, 2001).
Other mechanisms by which LRP-1 may regulate cell migra-
tion that are independent of uPAR include the recently
demonstrated interaction of LRP-1 with platelet-derived
growth factor BB (Loukinova et al., 2002) and the function
 
of LRP-1 in regulating fibronectin accumulation in associa-
tion with cells (Salicioni et al., 2002).
In this work, our major goals were to determine whether
LRP-1 regulates cell signaling through pathways other than
the Ras–ERK pathway and to identify novel mechanisms
whereby LRP-1 may control cell migration. To accomplish
these goals, it was essential to distinguish between pathways
that depend on uPAR and those that do not. Thus, we pre-
pared uPAR
 
 
 
/
 
 
 
 MEFs from embryos of crossbred het-
erozygous uPAR gene knockout mice. These cells demon-
strated substantially decreased Rac1 activation compared
with uPAR
 
 
 
/
 
 
 
 MEFs, suggesting that uPAR regulates
Rac1 when expressed at normal levels, as well as when it is
overexpressed (Kjoller and Hall, 2001). Because LRP-1
down-regulates cell-surface uPAR, LRP-1–deficient MEFs
and cells that were cultured in the presence of receptor-asso-
ciated protein (RAP) to neutralize the activity of LRP-1
(Webb et al., 1999) demonstrated substantially increased
Rac1 activation. Expression of the VLDLr in LRP-1–deficient
MEFs decreased Rac1 activation. When LRP-1 activity was
neutralized in uPAR-deficient cells, including uPAR
 
 
 
/
 
 
 
MEFs and LM-TK
 
 
 
 fibroblasts, Rac1 activation and cell
migration were unaffected. Thus, LRP-1 does not regulate
MEF/fibroblast migration by uPAR-independent mecha-
nisms that are masked when uPAR is expressed.
 
Results
 
Rac1 is suppressed in uPAR
 
 
 
/
 
 
 
 MEFs
 
Kjoller and Hall (2001) demonstrated that Rac1 is activated
in cells that overexpress uPAR. Because LRP-1 regulates the
level of cell-surface uPAR by promoting uPAR endocytosis
and catabolism (Conese et al., 1995; Webb et al., 2000), we
hypothesized that LRP-1 may function as a major regulator
of the basal level of Rac1 activation. To study the relation-
ship between uPAR and LRP-1 in Rac1 activation, heterozy-
gous (uPAR
 
 
 
/
 
 
 
) mice were bred and MEFs were isolated
from the embryos. A1 (uPAR
 
 
 
/
 
 
 
), B1 (uPAR
 
 
 
/
 
 
 
), and
C1 (uPAR
 
 
 
/
 
 
 
) cells were derived from littermates. A sec-
ond cell line with each genotype (uPAR
 
 
 
/
 
 
 
 A2 cells,
uPAR
 
 
 
/
 
 
 
 B2 cells, and uPAR
 
 
 
/
 
 
 
 C2 cells) was isolated
from separate matings.
Fig. 1 A shows a representative semi-quantitative PCR
analysis of the uPAR allele in A1, B1, and C1 cells. Because
murine uPAR-specific antibodies are not highly effective, we
used a previously described functional assay to quantitate
cell-surface uPAR (Weaver et al., 1997). The uPAR was
loaded with murine uPA, which was then detected based on
its ability to activate plasminogen. Under the conditions of
our assay, plasminogen activation and 
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L
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p
 
-nitroanilide (VLK-
 
p
 
NA) hydrolysis are linear functions of
the concentration of cell-associated uPA. We confirmed that
plasminogen activation was due to uPA, using the uPA-spe-
cific inhibitor amiloride (Weaver et al., 1997). Fig. 1 B shows
that cell-associated uPA was nearly undetectable in the
uPAR
 
 
 
/
 
 
 
 cells. Interestingly, the uPAR
 
 
 
/
 
 
 
 cells bound
 
 
 
50% of the uPA retained by uPAR
 
 
 
/
 
 
 
 cells. As shown in
Fig. 1 C, uPAR expression did not affect LRP-1 expression.
Transwell migration assays were performed using mem-
branes coated on the bottom surface with vitronectin. 10% 
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FBS was added to the lower migration chamber. Under
these conditions, MEF migration correlated with uPAR ex-
pression (Fig. 2 A). uPAR
 
 
 
/
 
 
 
 cells migrated more rapidly
than uPAR
 
 
 
/
 
 
 
 cells, which in turn migrated more rapidly
than uPAR
 
 
 
/
 
 
 
 cells. By contrast, uPAR expression did not
affect MEF migration on type I collagen. A selective rela-
tionship in which the uPA–uPAR system promotes cell mi-
gration on vitronectin and not type I collagen has been ob-
served previously in MCF-7 cells and in LRP-1–deficient
MEF-2 cells (Weaver et al., 1997; Nguyen et al., 1999).
Binding of uPA to uPAR activates ERK, and this pathway
is responsible for the effects of uPA on migration of MCF-7
and HT 1080 cells (Nguyen et al., 1999; Webb et al.,
2000). To test whether ERK activation is responsible for the
differences in migration of uPAR-positive and -negative
MEFs, we pretreated A1, B1, and C1 cells with the MEK
antagonist, PD098059. As shown in Fig. 2 B, PD098059
did not affect MEF migration, irrespective of the number of
copies of the uPAR allele. Equivalent results were obtained
with A2, B2, and C2 cells (not depicted). Dominant-nega-
tive MEK1 also failed to affect MEF migration, irrespective
of the uPAR expression level (Fig. 2 C).
Next, we tested whether uPAR expression affects Rac1 ac-
tivation in MEFs. We used an affinity pulldown assay to
detect GTP-loaded Rac1. Fig. 3 A shows that two sep-
arate uPAR
 
 
 
/
 
 
 
 cell lines (C1 and C2) demonstrated sig-
nificantly increased levels of GTP-Rac1, compared with
uPAR
 
 
 
/
 
 
 
 cells (A1 and A2). Furthermore, dominant-nega-
 
tive Rac1 (N17Rac1) selectively inhibited migration of the
uPAR
 
 
 
/
 
 
 
 cells (Fig. 3 B). When Rac1-dependent signaling
was antagonized, migration of uPAR
 
 
 
/
 
 
 
 and uPAR
 
 
 
/
 
 
 
cells was equivalent. These results demonstrate that naturally
occurring uPAR regulates Rac1 activation, and that this ac-
tivity is responsible for the effects of uPAR on MEF migra-
tion. The reason why inhibitors of ERK activation do not af-
fect MEF migration has not been definitively determined;
however, the level of endogenously produced uPA may be
insufficient. Furthermore, we have shown that MEFs express
 
 
 
V
 
 
 
3
 
 and use this integrin for adhesion to vitronectin (un-
published data). Previous studies have shown that activated
ERK is selective in promoting cell migration that is medi-
ated by 
 
 
 
v
 
 
 
5
 
 and not 
 
 
 
v
 
 
 
3
 
 (Yebra et al., 1996; Klemke et al.,
1997; Nguyen et al., 1999).
As further confirmation regarding the effects of uPAR on
Rac1 activation, we examined the morphology of uPAR
 
 
 
/
 
 
 
and uPAR
 
 
 
/
 
 
 
 cells at various times after plating in FBS-pre-
coated chamber slides. As shown in Fig. 4, both cell types
adopted spread morphologies within 1 h; however, very few
protrusions were seen in uPAR
 
 
 
/
 
 
 
 cells. By contrast,
Figure 1. Characterization of uPAR-deficient MEFs. (A) Genomic 
DNA PCR was performed to detect the intact uPAR allele in A1, B1, 
and C1 cells, using primers that hybridize with exon 3 of the uPAR 
gene. The PAI-1 allele was also detected as an internal control for 
total DNA. The lane labeled “control” shows DNA from the tail of a 
normal mouse. (B) Cell-surface uPAR in uPAR /  (A1 and A2), 
uPAR /  (B1 and B2), and uPAR /  (C1 and C2) cells was detected 
by plasminogen activation assay. 0.5 mM amiloride was added to 
some cultures to inhibit uPA-specific plasminogen activation. Substrate 
hydrolysis was standardized based on cell protein. (C) Expression of 
LRP-1 in uPAR /  (A1), uPAR /  (B1), and uPAR /  (C1) cells 
and in MEF-1 (LRP-1-positive) and MEF-2 (LRP-1-negative) cells was 
detected by immunoblot analysis using an antibody 11H4.
Figure 2. Migration of uPAR-deficient MEFs. (A) uPAR /  (A1 and 
A2), uPAR /  (B1 and B2), and uPAR /  (C1 and C2) MEFs were 
allowed to migrate through Transwell membranes that were precoated 
with purified vitronectin or type I collagen. Migrating cells were 
detected by crystal violet staining. (B) uPAR /  (A1), uPAR /  (B1), 
and uPAR /  (C1) MEFs were treated with DMSO ( ) or 10  M 
PD098059 ( ) for 15 min at RT and then allowed to migrate 
through Transwell membranes that were precoated with 20% FBS. 
Migrating cells were detected by crystal violet staining. (C) A1, B1, 
and C1 MEFs were cotransfected to express dominant-negative 
MEK1 (DN-MEK1) and pEGFP-N1. Control cells were cotransfected 
with equal amounts of empty vector (pBK-CMV) and pEGFP-N1. 
After culturing for 24 h, the cells were allowed to migrate for 4 h 
through serum-coated membranes. Migration was determined by 
fluorescence microscopy. Results are expressed relative to the 
migration rate of A1 cells that were cotransfected with pBK-CMV 
and pEGFP-N1 (mean   SEM).1064 The Journal of Cell Biology | Volume 159, Number 6, 2002
uPAR /  cells exhibited a polarized morphology with clearly
defined leading lamellipodia. The motile phenotype, which
was adopted only by uPAR /  cells, is consistent with the
demonstrated activation of Rac1 in uPAR-expressing cells.
LRP-1 suppresses basal levels of activated ERK and Rac1
Although we previously demonstrated that LRP-1–deficient
embryonic fibroblasts (MEF-2 cells) migrate more rapidly
than LRP-1–expressing MEFs (Weaver et al., 1997), this
difference was not explained by a change in cell signaling.
Fig. 5 shows the results of experiments comparing the levels
of ERK activation in MEF-1 and MEF-2 cells. Phosphory-
lated ERK was equivalent in MEF-1 and MEF-2 cells when
FBS was present; however, when the cells were serum-
deprived for 18 h, the level of phosphorylated ERK was signif-
icantly higher in the MEF-2 cells. Fig. 5 B shows ERK phos-
phorylation in MEF-2 cells as a function of time after serum
withdrawal. Initially, ERK phosphorylation drops precipi-
tously, but then recovers to near the level observed in the
presence of serum. This pattern is consistent with a model in
which an autocrine signaling pathway is established, involv-
ing ligands that accumulate in the absence of LRP-1. Al-
though we did not attempt to identify a responsible ligand
or ligands, the uPA–uPAR system has been characterized as
a potent autocrine signaling system leading to ERK activa-
tion (Aguirre-Ghiso et al., 1999; Ma et al., 2001). Because
uPA accumulates to greatly increased levels in the medium
of MEF-2 cells compared with MEF-1 cells (Weaver et al.,
1997), it is likely that the uPA–uPAR system is at least par-
tially responsible for the increase in ERK phosphorylation in
LRP-1–deficient MEF-2 cells after serum withdrawal.
Next, we compared the levels of activated Rac1 in MEF-1
and MEF-2 cells that were plated in serum-containing me-
dium and cultured for 18 h. As shown in Fig. 6 A, the level
of activated Rac1 was increased in the MEF-2 cells, relative
to the MEF-1 cells, by 3.1   0.8-fold. The increase in acti-
vated Rac1 was statistically significant (P   0.05, n   6).
The VLDLr and LRP-1 function equivalently as regula-
tors of the uPA–uPAR system (Webb et al., 2000) and dem-
onstrate substantial overlap in ligand-binding specificity
(Strickland et al., 2002). To confirm the role of LRP-1 as a
regulator of Rac1 activation in MEFs, we transfected MEF-2
cells to express the VLDLr. Immunoblot analysis was used
to confirm VLDLr expression (Fig. 6 B). GTP-loaded Rac1
was decreased by 64   7% in the VLDLr-expressing cells.
This value represents a minimum estimate because we ana-
lyzed complete cultures in which probably only  80% of
the cells expressed the VLDLr. Thus, the VLDLr reversed
the phenotype associated with LRP-1 deficiency, suppress-
ing Rac1 activation in the MEF-2 cells.
To determine whether uPAR is required in the mecha-
nism by which LRP-1 regulates Rac1, we cultured uPAR / 
and uPAR /  MEFs in the presence of RAP for 3 d. RAP
Figure 3. uPAR regulates Rac1 activation in MEFs. (A) uPAR /  
(A1 and A2) and uPAR /  (C1 and C2) MEFs were cultured in serum-
supplemented medium for 18 h and then extracted to detect GTP-
loaded Rac1. (B) uPAR /  (A1 and A2) and uPAR /  (C1 and C2) 
MEFs were cotransfected with constructs encoding N17Rac1 and 
pEGFP-N1 or with pBK-CMV (empty vector) and pEGFP-N1. Cell 
migration was studied using serum-coated membranes. Migration 
was determined by fluorescence microscopy. Results are expressed 
relative to the migration rate of A1 cells that were cotransfected 
with pBK-CMV and pEGFP-N1 (mean   SEM).
Figure 4. uPAR expression alters the morphology 
of MEFs. uPAR /  C1 cells and uPAR /  A1 
cells were plated in serum-coated chamber slides 
for the indicated times and stained with 
rhodamine-conjugated phalloidin. Images were 
collected by fluorescence microscopy. Bar, 10  m. Regulation of Rac1 by LRP-1 | Ma et al. 1065
neutralizes the ligand-binding activity of LRP-1, and as a re-
sult, up-regulates specific proteins in the plasma membrane,
including uPAR (Webb et al., 1999). As shown in Fig. 6 C,
RAP significantly increased the level of GTP-loaded Rac1
only in the uPAR /  MEFs (P   0.05). No increase in
Rac1 activation was observed in the uPAR /  cells, sug-
gesting that uPAR is essential for the regulation of Rac1 by
LRP-1.
As a second model system to examine the effects of sus-
tained LRF neutralization on Rac1 activation and to further
test the role of uPAR, we cultured L929 and LM-TK
  cells
in the presence or absence of RAP for 3 d. LM-TK
  cells
are derived from L929 cells, but have lost genes encoding
essential products for anchoring glycosylphosphatidylinosi-
tol (GPI)-linked proteins (Singh et al., 1991). We con-
firmed that L929 cells express cell-surface uPAR and that
LM-TK
  cells do not using our plasminogen activation as-
say (not depicted). Fig. 6 D shows that RAP increased Rac1
activation in the L929 cells (P   0.05) but not in the LM-
TK
  cells. Again, these results are consistent with a model
in which LRP-1 regulates Rac1 by a mechanism that re-
quires uPAR.
LRP-1 regulates MEF migration by suppressing 
Rac1 activation
Images of phalloidin-stained MEF-1 and MEF-2 cells are
shown in Fig. 7. LRP-1–deficient MEF-2 cells spread rap-
idly and then developed numerous lamellipodia that were
obvious within 4 h of plating. By contrast, MEF-1 cells re-
quired more time to spread. By 4 h, most of the MEF-1 cells
had adopted a spread phenotype; however, these cells dem-
onstrated fewer well-developed lamellipodia. The difference
in MEF phenotype is consistent with the selective activation
of Rac1 in MEF-2 cells.
In Transwell migration assays, MEF-2 cells migrated
more rapidly than MEF-1 cells (Fig. 8), confirming the re-
sults of our previously reported monolayer denudation ex-
periments (Weaver et al., 1997). PD098059 and dominant-
negative MEK1 failed to significantly affect migration of
the MEF-1 or MEF-2 cells. By contrast, N17Rac1 selec-
tively inhibited MEF-2 cell migration, reducing the rate to
that observed with MEF-1 cells. These results and the re-
sults of our experiments with uPAR /  and uPAR / 
MEFs demonstrate the importance of Rac1 in regulating
MEF migration. Furthermore, these results demonstrate
that regulation of Rac1 by LRP-1 affects an important
physiologic property of the cell.
Figure 5. LRP-1 expression suppresses ERK activation in serum-
deprived MEFs. (A) MEF-1 (LRP / ) and MEF-2 (LRP / ) cells 
were extracted without serum deprivation or after serum deprivation 
for 18 h. Phosphorylated and total ERK were detected by immunoblot 
analysis. (B) ERK phosphorylation in MEF-2 cells was determined as 
a function of time after serum deprivation.
Figure 6. LRP-1 suppresses Rac1 activation. (A) MEF-1 and MEF-2 
cells were cultured in DME and 10% FBS for 18 h and then 
extracted to detect activated and total Rac1. The level of activated 
Rac1 (standardized based on total Rac1) was determined by 
densitometry scanning using ImageQuant software to generate the 
values shown in the bar graph (mean   SEM, n   3). The asterisk 
indicates statistical significance (unpaired t test, P   0.05). (B) MEF-2 
cells were transfected to express VLDLr or with empty vector 
(pRc/CMV). Expression of the VLDLr and Rac1 activation were 
determined 4 d later. The level of activated Rac1 in VLDLr-expressing 
MEF-2 cells, compared with vector-transfected control cells, is 
shown in the bar graph (mean   SEM, n   3). The asterisk indicates 
statistical significance (unpaired t test, P   0.05). (C) uPAR-deficient 
A1 cells and uPAR-expressing C1 cells were cultured in the 
absence ( ) or presence ( ) of 200 nM GST-RAP for 3 d. Rac1 
activation was then determined. The values shown in the bar graph 
are standardized against uPAR /  cells that were not treated with 
RAP (mean   SEM, n   3). The asterisk indicates a statistical 
significance between C1 cells that were cultured in the presence 
and absence of RAP (unpaired t test, P   0.05). (D) LM-TK
  and 
L929 cells were cultured in the presence or absence of 200 nM 
GST-RAP for 3 d. Rac1 activation was then determined. The bar 
graph shows values that were standardized against activated Rac1 
in LM-TK
  cells or L929 cells that were not RAP-treated (mean   SEM, 
n   3). The asterisk indicates that Rac1 activation in L929 cells 
treated with RAP was significantly different from Rac1 activation in 
the same cells that were not treated with RAP (unpaired t test, 
P   0.05). In control experiments, we demonstrated that GST does 
not affect Rac1 activation (not depicted).1066 The Journal of Cell Biology | Volume 159, Number 6, 2002
LRP-1 does not regulate cell migration 
in uPAR-deficient cells
Our uPAR /  MEFs provided an opportunity to probe for
uPAR-independent mechanisms whereby LRP-1 may regu-
late cell migration. When cultured in the presence of RAP
for 3 d, uPAR-deficient MEFs (A1 and A2 cells) failed to
demonstrate altered cell migration (Fig. 9 A). Under the
same treatment conditions, uPAR /  and uPAR /  cells
demonstrated increased migration, as was anticipated due to
the effects of RAP on Rac1 activation.
Identical experiments were performed with LM-TK
  and
L929 cells. Because LM-TK
 cells lack all GPI-anchored
proteins in addition to uPAR, this system is less specific than
the MEF system. However, when LM-TK
  cells were cul-
tured in the presence of RAP for 3 d, cell migration was un-
changed (Fig. 9 B). By contrast, RAP treatment promoted
L929 cell migration on vitronectin. Interestingly, L929 cell
migration on fibronectin was also promoted. Thus, in two
separate model systems, neutralizing the activity of LRP-1
failed to affect cell migration when uPAR is not present.
Discussion
LRP-1 gene deletion in mice is embryonic lethal (Herz et al.,
1992), and the lethality has not been explained. Conditional
LRP-1 gene targeting in the liver, using the Cre–loxP sys-
tem, demonstrated a role for LRP-1 in the clearance of chy-
lomicron remnants (Rohlmann et al., 1998); however, other
LRP-1 functions were not addressed. Understanding the
function of LRP-1 at the level of the cell may provide im-
Figure 7. The morphology of LRP-1-expressing and -deficient 
MEFs. MEF-1 and MEF-2 cells were plated in serum-coated chamber 
slides for the indicated times and stained with rhodamine-conjugated 
phalloidin. Images were collected using the fluorescence microscope. 
Bar, 10  m.
Figure 8. ERK and Rac1 in migration of LRP-1-deficient MEFs. 
(A) MEF-1 and MEF-2 cells were treated with 10  M of the MEK 
inhibitor, PD098059 or with vehicle (DMSO) for 15 min at RT, and 
were then allowed to migrate through serum-coated Transwell 
membranes. The number of migrating cells was determined by crystal 
violet staining. (B) MEF-1 and MEF-2 cells were cotransfected to 
express dominant-negative MEK1 (DN-M) or dominant-negative Rac1 
(DN-R) and GFP. Control cells were transfected with empty vector 
(pBK-CMV) and pEGFP-N1. Cell migration experiments were 
performed 24 h after transfection. Migration was determined by 
fluorescence microscopy. Results are expressed relative to the 
migration rate in MEF-1 cells transfected with pBK-CMV and 
pEGFP-N1 (n   4). The asterisk indicates statistical significance at 
the P   0.05 level.
Figure 9. Effects of LRP-1 neutralization on MEF migration in the 
absence of uPAR. (A) uPAR /  (A1 and A2), uPAR /  (B1 and 
B2), and uPAR /  (C1 and C2) MEFs were cultured in the presence 
or absence of 200 nM GST-RAP for 3 d. Cells were allowed to 
migrate through Transwell membranes that were precoated with 
FBS. Migration was determined by crystal violet staining. The asterisk 
indicates that the bar is significantly different from the control 
(no RAP treatment; unpaired t test, P   0.01, n   3). (B) Migration 
of LM-TK
  and L929 cells was studied after culturing these cells in 
the presence or absence of GST-RAP for 3 d. Cells were allowed to 
migrate through Transwell membranes that were precoated with 
vitronectin or fibronectin. Cell migration was determined by crystal 
violet staining. The asterisk indicates statistical significance (unpaired 
t test, P   0.01; n   3). Regulation of Rac1 by LRP-1 | Ma et al. 1067
portant clues as to the function of this receptor in normal
physiology and in disease.
Cell migration is critical in embryonic development and
in both physiologic and pathophysiologic processes in the
adult, including inflammation, wound repair, atherogenesis,
and cancer invasion (Horwitz and Parsons, 1999). Within
the cell, signaling cascades that regulate cell migration may
be compartmentalized so that different signals impact on
processes occurring at the leading edge, in the cell body, and
in the trailing uropod. Signaling proteins that function pref-
erentially at the leading edge, including Rac1, typically regu-
late new actin polymerization (Kraynov et al., 2000; Ridley
et el., 2001). RhoA and its downstream effector, Rho kinase,
may act selectively in the uropod by loosening integrin-
based adhesions (Worthylake et al., 2001). The subcellular
sites where ERK and MLCK function are less clear. These
proteins may have a role in uropod retraction; however,
MLCK has been selectively localized to lamellipodia, indi-
cating a potentially important role in promoting contractil-
ity at this site (Chew et al., 2002). Evidence presented here
and in our previous work (Webb et al., 2000) demonstrates
that LRP-1 suppresses activation of both Rac1 and the Ras-
ERK pathway and may therefore inhibit cell migration by
regulating two distinct signaling pathways.
The function of LRP-1 as a major regulator of the basal
level of Rac1 activation is based on its ability to mediate
uPAR endocytosis and substantially down-regulate cell-sur-
face uPAR (Conese et al., 1995). LRP-1 gene neutralization
in MEFs is associated with a 2.4-fold increase in cell-surface
uPAR (Weaver et al., 1997). Similarly, LRP-1 antisense
RNA expression in HT 1080 cells increases cell-surface
uPAR by 2.4-fold (Webb et al., 2000), and neutralizing the
activity of the VLDLr with RAP in MCF-7 cells increases
cell-surface uPAR by threefold (Webb et al., 1999). These
results suggest that the effects of LRP-1 and the VLDLr on
cell-surface uPAR are similar, and the method used to neu-
tralize these LRFs does not significantly affect the magnitude
of the subsequent increase in cell-surface uPAR. LRP-1 de-
creases the amount of uPAR available to bind to vitronectin,
which is apparently the event responsible for Rac1 activation
(Kjoller and Hall, 2001).
In their original work, Kjoller and Hall (2001) overex-
pressed uPAR in Swiss 3T3 cells, NIH 3T3 cells, and
COS-7 cells and demonstrated morphologic changes
consistent with Rac1 activation. They also directly dem-
onstrated increased GTP-bound Rac1 in uPAR-overex-
pressing NIH 3T3 cells. Unpublished studies from our lab-
oratory have demonstrated that COS-7 cells express very
low levels of cell-surface uPAR; however, murine fibro-
blasts typically express higher amounts. Thus, the activities
observed by Kjoller and Hall (2001) probably represent the
effects of uPAR, produced by the expression vector, super-
imposed on the activity of naturally occurring uPAR. Our
experiments with MEFs prepared from gene knockout em-
bryos demonstrate that naturally occurring uPAR is also an
important regulator of Rac1 activation. Overexpression is
not necessary to observe this activity. uPAR /  MEFs
demonstrated a substantial decrease in Rac1 activation, de-
creased migration on vitronectin, and altered morphology,
consistent with Rac1 deactivation.
Regulation of Rac1 by LRP-1 was observed in serum-con-
taining medium. By contrast, the effects of LRP-1 on ERK
activation were observed only in serum-free medium. The
ability of serum to override the function of LRP-1 as a regu-
lator of ERK stresses the importance of the cellular microen-
vironment in determining the activity level of signaling pro-
teins, such as ERK, which serve as convergence points for
numerous pathways initiated by integrins and growth factor
receptors (Schwartz and Ginsberg, 2002). In multicellular
tissues, LRP-1–expressing cells may be exposed to growth
factors and regulatory molecules that differ from those
present in serum or in medium that is conditioned by a sin-
gle cell type. Furthermore, the concentration of uPA in the
microenvironment of the cell will be influenced not only by
the cell that expresses the uPA, but also by other cells that
express uPAR and/or LRFs capable of uPA catabolism.
These factors may all contribute in determining whether
LRP-1 regulates ERK in vivo.
Although for the most part, our data support a model in
which ligation of vitronectin is necessary for uPAR signaling
to Rac1, some inconsistent results remain to be clarified. For
example, we previously demonstrated that when cultured on
fibronectin-coated surfaces, LRP-1–deficient MEF-2 cells
demonstrate increased migration compared with MEF-1
cells (Weaver et al., 1997). Similarly, in this paper, we dem-
onstrated that RAP-treated L929 cells migrate at an in-
creased rate not only on vitronectin-coated surfaces, but also
on fibronectin-coated surfaces. The role of Rac1 in mediat-
ing these LRP-1–dependent changes when vitronectin is not
available to bind uPAR remains to be established.
An intimate relationship between LRP-1 (or the VLDLr)
and the uPA–uPAR system in regulating cell signaling and
migration has now been established in MEFs, fibroblasts, fi-
brosarcoma cells, and in some carcinoma cells. Although the
effects of uPAR and LRP-1 on cell migration may be cell
type-specific, conserved properties have emerged. LRP-1
down-regulates the uPA–uPAR system by promoting catab-
olism of both uPA and uPAR (Kounnas et al., 1993; Conese
et al., 1995; Webb et al., 1999). With regard to this func-
tion, studies presented here and elsewhere (Webb et al.,
2000) suggest that LRP-1 and the VLDLr are interchange-
able. When LRP-1 is neutralized, the concentration of
uPAR in the plasma membrane increases; however, a new
equilibrium is established in which alternative uPAR cata-
bolic pathways are operational (Nykjaer et al., 1998; Webb
et al., 1999). The increase in cell-surface uPAR results in ac-
tivation of downstream cell-signaling pathways.
Because of our focus on cell migration and because we de-
sign many of our experiments to analyze cell signaling in the
absence of exogenously added growth factors or stimulatory
molecules, our results regarding the effects of LRP-1 on cell
physiology have consistently revealed the potency of the
uPA–uPAR system. If LRP-1 regulates a receptor other than
uPAR that is involved in cell migration, this activity may not
have been detected in our experiments if the required ligand
was not present in the serum added to the lower Transwell
chamber or produced by the cells themselves. There is grow-
ing evidence for uPAR-independent pathways by which
LRP-1 regulates cell physiology. For example, by binding
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proteins, LRP-1 may regulate cell growth and apoptosis
(Lutz et al., 2002). Furthermore, by binding platelet-derived
growth factor BB, LRP-1 may regulate the function of
PDGF   receptor (Boucher et al., 2002; Loukinova et al.,
2002). In smooth muscle cells, neutralizing the activity of
LRP-1 with RAP inhibits cell migration (Okada et al., 1996;
Wijnberg et al., 1997), which is the reverse effect compared
with what we have observed in other cell types. Thus,
smooth muscle cells may represent an important model system
for identifying uPAR-independent mechanisms whereby LRP-1
regulates cell physiology.
Materials and methods
Antibodies and reagents
[Glu
1]plasminogen was purified from human plasma by the method of
Deutsch and Mertz (1970). Vitronectin was purified by the method of Ya-
tohogo et al. (1988), and fibronectin by the method of Ruoslahti et al.
(1982). Type I collagen was purchased from Collaborative Biochemical
Products. GST-RAP was expressed and purified as described previously
(Webb et al., 1999). Recombinant GST was prepared for control experi-
ments. mAb 11H4, which recognizes the 85-kD LRP-1 light chain (Kowal
et al., 1989), was purified from ascites fluid after inoculation of hybridoma
cells obtained from the American Type Culture Collection (ATCC). Phos-
pho-ERK–specific antibody and the MEK inhibitor PD098058 were pur-
chased from Calbiochem. Total ERK was detected using an antibody pur-
chased from Zymed Laboratories. Rac1-specific mAb was purchased from
BD Biosciences. Peroxidase-conjugated anti–rabbit IgG and anti–mouse
IgG were purchased from Sigma-Aldrich.
Rac/Cdc42 assay reagent, which includes residues 67–150 of p21-acti-
vated kinase fused to GST and coupled to glutathione-agarose was pur-
chased from Upstate Biotechnology. The expression vector pRSVBneoTAg,
which encodes SV40 large T antigen, was provided by Dr. Jim Pipas (Uni-
versity of Pittsburgh, Pittsburgh, PA). pEGFP-N1, which encodes GFP, was
purchased from CLONTECH Laboratories, Inc. pKH3-N17Rac1, which en-
codes dominant-negative Rac1 (S17 → N; N17Rac1), was provided by Dr.
Ian Macara (University of Virginia, Charlottesville, VA). The VLDLr expres-
sion construct in pRc/CMV (pRc/VLDLr) and VLDLr-specific pAb were pro-
vided by Drs. Keith McCrae and Matt Gafvels (Case Western Reserve
University, Cleveland, OH). pBABE-DN-MEK1, which encodes dominant-
negative rabbit MEK1 (S217 → A; DN-MEK1), was provided by Dr. An-
drew Catling (University of Virginia). LipofectAMINE™ was provided by
Invitrogen. VLK-pNA was purchased from Chromogenix.
Cell lines
LRP-1–deficient MEFs (referred to interchangeably as MEF-2 or PEA-13
cells in the literature) and LRP-1–expressing MEF-1 cells were obtained
from the ATCC and cultured in DME with 10% FBS and penicillin/strepto-
mycin. Murine L929 and LM-TK
  fibroblasts also were obtained from the
ATCC and cultured in the same medium. LM-TK
  cells are derived from
L929 cells, but lack critical genes for the proper formation of GPI anchors
(Singh et al., 1991).
uPAR gene knockout mice that have been described previously (Dew-
erchin et al., 1996) were obtained from Dr. Peter Carmeliet (KU Leuven,
Belgium). These mice were crossbred with wild-type C57B16/J mice
(Jackson ImmunoResearch Laboratories). The resulting uPAR( / ) mice
were then crossbred to generate uPAR( / ), uPAR( / ), and uPAR( / )
embryos that were killed at post-implantation day 12.5–14.5. Primary
embryonic fibroblasts were prepared essentially as described previously
(Herz et al., 1992), using torsos from which the heads and livers had been
removed. The cells were cultured in DME with 10% FBS. Genotypes were
established for individual embryos by semi-quantitative PCR, using ge-
nomic DNA extracted from embryonic livers. The PCR primers for uPAR
amplify a template in exon 3 (Bugge et al., 1996). As an internal refer-
ence, a template from exon 2 in the PAI-1 gene was amplified using the
primers 5 -CCTCATCCTGGGCCTGGTTCTGGTCT-3  and 5 -GGTTTTC-
CCCGCTGTGGTCATCTGC-3 . Further confirmation of the genotypes
was obtained by performing PCR for the neo insert (present only when
the gene is absent) as well as by Southern blot analysis. For Southern
blots, DNA was digested with BamHI, subjected to electrophoresis on
0.8% agarose gels, and probed with a fragment of the neo gene that de-
tects a 5.5-kb band.
MEFs from uPAR / , uPAR / , and uPAR /  embryos were immor-
talized by transfection to express SV-40 large T antigen. Transfected cells
were selected for 3 wk in 1 mg/ml G418. A1 cells (uPAR / ), B1 cells
(uPAR / ), and C1 cells (uPAR / ) were derived from embryos of a sin-
gle breeding. A2 cells (uPAR / ), B2 cells (uPAR / ), and C2 cells
(uPAR / ) were from separate litters.
Transient transfection protocols
For cell migration experiments, MEF-1, MEF-2, uPAR / , uPAR / , and
uPAR /  MEFs (3   10
5) were cotransfected with constructs encoding 1.5
 g dominant-negative MEK1 or 1.5  g dominant-negative Rac1 and 0.5
 g of pEGFP-N1 by incubation for 4.5 h with 12  l LipofectAMINE™.
Control cells were cotransfected with empty vector (pBK-CMV) and
pEGFP-N1. Transfected cells were cultured for 24 h before analysis. For
Rac1 activation experiments, MEF-2 cells (6   10
5) were transfected with
pRc/VLDLr, pRc/CMV, or pEGFP-N1 (6  g) using 36  l LipofectAMINE™.
Transfection efficiencies were  80%, as determined by counting green
fluorescent cells in preparations transfected with pEGFP-N1. Cotransfec-
tion efficiencies were determined as described previously (Nguyen et al.,
1999), and were always essentially 100%.
Activity assay for the determination of cell-surface uPAR
MEF-2 cells, which provide a rich source of murine uPA (Weaver et al.,
1997), were cultured in serum-free DME for 24 h. Conditioned medium
was collected and subjected to centrifugation at 2,000 g to remove cellular
debris and then concentrated 20-fold using Centricon concentrators with
10-kD exclusion filters (Amicon; Millipore).
L929 cells, LM-TK
  cells, uPAR /  MEFs, uPAR /  MEFs, and
uPAR /  MEFs were plated at 2.8   10
5 cells/well in 24-well plates and
cultured overnight. The cells were subjected to a mild acid wash as de-
scribed previously (Ma et al., 2001), and were then incubated with con-
centrated conditioned medium from MEF-2 cells for 1 h at 4 C. After wash-
ing the cultures three times with Earle’s balanced salt solution, 25 mM
Hepes, and 5 mg/ml BSA, pH 7.4, the cells were reconstituted in 1 ml of
the same buffer supplemented with 1  M [Glu
1]plasminogen and 0.5 mM
VLK-pNA. 0.5 mM amiloride was added to some cultures to specifically
inhibit uPA and not tissue-type plasminogen activator (Weaver et al.,
1997). Plasminogen activation was allowed to proceed for 3 h at 37 C.
Hydrolysis of VLK-pNA was detected by measuring the absorbance at 405
nm. To standardize the activity assay, cellular protein was determined by
fluoraldehyde assay.
Cell migration assays
6.5-mm Transwell membranes (8.0- m pores; Costar) were coated on the
underside only with 20% FBS, 5  g/ml purified vitronectin, 10  g/ml fi-
bronectin, or 25  g/ml type I collagen for 2 h at 37 C. Vitronectin is the
principal protein that coats membranes that are treated with FBS (Hayman
et al., 1985). Both membrane surfaces were blocked with 5 mg/ml BSA.
Cells were dissociated from monolayer culture, washed in serum-free me-
dium, and transferred to the top chamber of each Transwell unit at a den-
sity of 10
6 cells/ml in 100  l DME. The bottom chamber contained DME
and 10% FBS. Some cells were pretreated for 15 min with 10  M of the
MEK inhibitor PD098059. Other cells were cultured for 3 d in medium
supplemented with 200 nM GST-RAP or GST. When these protocols were
executed, the same agent (GST-RAP or PD098059) was added to both
Transwell chambers. Migration was allowed to proceed for 6 h at 37 C.
Nonmigrating cells were removed from the top surfaces of the Transwell
membranes using cotton swabs. The membranes were then fixed in metha-
nol and stained with 0.1% crystal violet. The dye was eluted with 10%
acetic acid, and the absorbance of the eluate was determined at 570 nm.
In control experiments, we confirmed that crystal violet absorbance is a
linear function of cell number.
To study migration of GFP-expressing cells, translucent BioCoat™ Cell
Culture Inserts (BD Biosciences) were used instead of Transwell chambers.
The insert membranes had 8- m pores and were coated on the underside
surfaces with 20% FBS. Cells that were cotransfected with signaling effec-
tor mutants and pEGFP-N1 or with empty vector and pEGFP-N1 were
added to the top chamber and allowed to migrate for 4 h at 37 C. Nonmi-
grating cells were removed and the membranes were fixed in 4% PFA. Mi-
grating cells were then counted by fluorescence microscopy.
ERK activation
Phosphorylated and total ERK were detected by immunoblot analysis. Sub-
confluent cultures were incubated in serum-containing or serum-free me-
dium for the indicated times. The medium was then replaced with 20 mM Regulation of Rac1 by LRP-1 | Ma et al. 1069
ice-cold sodium phosphate, 150 mM NaCl, pH 7.4, containing 1 mg/ml
sodium orthovanadate. Cells were extracted in 1.0% NP-40, 50 mM
Hepes, 100 mM NaCl, 2 mM EDTA, 1  g/ml leupeptin, 100 KIU/ml apro-
tinin, 0.4 mg/ml sodium orthovanadate, 0.4 mg/ml sodium fluoride, and 5
mg/ml dithiothreitol, pH 7.4. Equal amounts of cell extract were subjected
to SDS-PAGE on 10% slabs. Proteins were transferred to nitrocellulose
membranes and probed with antibodies that detect phosphorylated and to-
tal ERK. Primary antibodies were detected using peroxidase-conjugated
anti–rabbit IgG and ECL.
Rac1 activation
Under our standard conditions, cells were maintained for 18 h after plating
in 10% FBS-supplemented medium before performing assays to detect ac-
tivated Rac1. In some experiments, cells were cultured in the presence or
absence of 200 nM GST-RAP for 3 d. The medium was changed every day
and fresh GST-RAP was added.
Cell extracts were prepared at 4 C from equal amounts of cell protein,
using prechilled GST-PAK-CRIB assay buffer (50 mM Tris-HCl, pH 7.4, 2
mM MgCl2, 1% vol/vol NP-40, 10% glycerol, 100 mM NaCl, 1  g/ml leu-
peptin, 100 KIU/ml aprotinin, 0.4 mg/ml sodium orthovanadate, and
0.4  mg/ml sodium fluoride). Extracts were cleared by centrifugation at
11,000 g for 2 min at 4 C in the presence of Sepharose CL-4B. 30- l sam-
ples were withdrawn for analysis of total Rac1. The remainder of each
extract was incubated for 45 min at 4 C with 7.5  l of p21-activated ki-
nase-PBD agarose (50% slurry), which selectively binds the active or GTP-
loaded forms of Rac and Cdc42. The beads were washed three times with
assay buffer and eluted with SDS-PAGE sample buffer. The eluates were
then subjected to immunoblot analysis using Rac1-specific antibody.
Fluorescence microscopy
MEF-1, MEF-2, uPAR /  C1 cells, and uPAR /  A1 cells were plated in
serum-coated chamber slides (10
4 cell per well) for the indicated times
(0.5–4 h) and fixed in 4% PFA for 20 min at 25 C. After fixation, cells were
permeabilized with 0.2% Triton X-100 and then blocked with 20% goat
serum in 20 mM sodium phosphate, 150 mM NaCl, pH 7.4 (PBS), for 1 h
at 25 C. The cells were then incubated for 1 h at 25 C with rhodamine-
conjugated phalloidin (1:500 dilution; Molecular Probes, Inc.) in PBS with
5% goat serum. Fluorescence microscopy was performed using a
rhodamine/TRITC cube (excitation BP520–550, barrier filter BA580IF,
dichroic mirror DM565). Images were collected using a cooled CCD cam-
era (Orca II; Hamamatsu Corporation) attached to a Nikon TE-300 inverted
microscope with a 60  objective (NA 1.4).
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